Evidence map›Paper›PMID 38976079›Full record

SynthesisJournal of gastrointestinal cancer2024

The Current Landscape of Clinical Trials for Immunotherapy in Pancreatic Cancer: A State-of-the-Art Review.

Zouina Sarfraz, Azza Sarfraz, Muhammad Danyal Farooq, Musfira Khalid, Khadija Cheema, Faheem Javad, Taleah Khan, Zainab Pervaiz, Muzna Sarfraz, Ali Jaan and 2 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of gastrointestinal cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Updates in Immunotherapy for Pancreatic Cancer.Journal of clinical medicine · 2024
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zouina SarfrazDepartment of Medicine, Fatima Jinnah Medical University, Queen's Road, Mozang Chungi, Lahore, Pakistan. zouinasarfraz@gmail.com.
Azza SarfrazThe Aga Khan University, Karachi, Pakistan.
Muhammad Danyal FarooqAl Nafees Medical College, Islamabad, Pakistan.
Musfira KhalidDepartment of Medicine, Fatima Jinnah Medical University, Queen's Road, Mozang Chungi, Lahore, Pakistan.
Khadija CheemaTucson Medical Center, Tucson, AZ, USA.
Faheem JavadAl Nafees Medical College, Islamabad, Pakistan.
Taleah KhanCMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan.
Zainab PervaizCMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan.
Muzna SarfrazKing Edward Medical University, Lahore, Pakistan.
Ali JaanRochester General Hospital, Rochester, NY, USA.
Subhan SadiqThe Aga Khan University, Karachi, Pakistan.
Junaid AnwarBaptist Hospitals of Southeast Texas, Beaumont, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic cancer remains a lethal malignancy with a 5-year survival rate below 6% and about 500,000 deaths annually worldwide. Pancreatic adenocarcinoma, the most prevalent form, is commonly associated with diabetes, chronic pancreatitis, obesity, and smoking, mainly affecting individuals aged 60 to 80 years. This systematic review aims to evaluate the efficacy of immunotherapeutic approaches in the treatment of pancreatic cancer.

methodsA systematic search was conducted to identify clinical trials (Phases I-III) assessing immunotherapy in pancreatic cancer in PubMed/Medline, CINAHL, Scopus, and Web of Science, adhering to PRISMA Statement 2020 guidelines. The final search was completed on May 25, 2024. Ongoing trials were sourced from ClinicalTrials.gov and the World Health Organization's International Clinical Trials Registry Platform (ICTRP). Keywords such as "pancreatic," "immunotherapy," "cancer," and "clinical trial" were used across databases. Gray literature was excluded.

resultsPhase I trials, involving 337 patients, reported a median overall survival (OS) of 13.6 months (IQR: 5-62.5 months) and a median progression-free survival (PFS) of 5.1 months (IQR: 1.9-11.7 months). Phase II/III trials pooled in a total of 1463 participants had a median OS of 12.2 months (IQR: 2.5-35.55 months) and a median PFS of 8.8 months (IQR: 1.4-33.51 months).

conclusionsImmunotherapy shows potential for extending survival among pancreatic cancer patients, though results vary. The immunosuppressive nature of the tumor microenvironment and diverse patient responses underline the need for further research to optimize these therapeutic strategies.

Indexed as

ImmunotherapyPancreatic NeoplasmsClinical Trials as TopicHumansImmune Checkpoint InhibitorsImmune Checkpoint InhibitorsClinical trialsDiagnosis and therapyImmunotherapyPancreatic cancerTranslational oncology

Identifiers

PMID38976079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.